View Future GrowthRegent Pacific Group 過去の業績過去 基準チェック /06Regent Pacific Groupは12.9%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.7%毎年増加している。売上は減少しており、年平均50.5%の割合である。主要情報12.92%収益成長率25.37%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率-50.49%株主資本利益率n/aネット・マージン-1,297.52%前回の決算情報31 Dec 2025最近の業績更新お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025お知らせ • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025お知らせ • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024お知らせ • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023すべての更新を表示Recent updatesお知らせ • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kongお知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025お知らせ • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kongお知らせ • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025お知らせ • Dec 19Regent Pacific Group Limited Announces Submission of Senstend New Drug Application to the National Medical Products Administration in ChinaThe Board announced that commercial strategic partner Jiang Su Wan Bang Sheng Hua Yi Yao Ji Tuan You Xian Ze Ren Gong Si (Jiangsu Wanbang Biopharmaceutical Group Co. Ltd.) ("Wanbang Biopharmaceutical", a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. ("Fosun")) has submitted the New Drug Application ("NDA") registration dossier with the National Medical Products Administration ("NMPA") on 17 December 2024, with approval expected within 12 months from the submission date. Wanbang Biopharmaceutical is responsible, at its own expense, for obtaining the NDA from NMPA and maintaining any and all regulatory approvals required for the importation of Senstend in the People's Republic of China ("China" or "PRC"). In addition, and importantly, Wanbang Biopharmaceutical has signed an exclusive manufacturing and supply agreement with, inter alia, Genetic S.p. A. ("Genetic") and Jiang Su Wan Bang Yi Yao Ying Xiao You Xian Gong Si (Wanbang Pharmaceutical Marketing and Distribution Co. Ltd) ("Wanbang MKT", an affiliate of Wanbang Biopharmaceutical) on 26 August 2024, where Genetic will manufacture and supply Senstend to Wanbang Biopharmaceutical based on purchase orders received from Wanbang Biopharmaceutical. As previously mentioned, on the NDA being approved by NMPA, USD 5 million (or approximately HKD 39 million) and on first commercial launch USD 2 million (or approximately HKD 15.60 million) will be payable to the Group from Wanbang Biopharm pharmaceutical.お知らせ • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, May 30, 2024Regent Pacific Group Limited, Annual General Meeting, May 30, 2024, at 15:00 China Standard Time. Location: 14/F, Fairmont House, 8 Cotton Tree Drive, Central Hong Kong Agenda: To receive, consider and adopt the audited financial statements of the Company and the reports of the Directors and the independent auditor of the Company for the year ended 31 December 2023; to re-appoint RSM Hong Kong as the independent auditor of the Company and to authorise the Board to fix their remuneration; to re-elect the following Directors, each as a separate ordinary resolution, and to authorise the Board to fix the remuneration of the Directors for the year ending 31 December 2024; and to consider other matters.お知らせ • Mar 26Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million.Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million on March 24, 2024. The consideration consists of CNY 8 million in cash. As part of the consideration, CNY 8 million was paid towards common equity. . West China Coking & Gas Company Limited reported the unaudited net loss of CNY 8.9 million as at 31 December 2023. The completion of the transaction is conditional upon all necessary corporate, governmental or regulatory approvals of the Disposal (the “Conditions”) including but not limited to unanimous approval from the shareholders of the Target Company and any relevant PRC governmental or regulatory bodies.お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024お知らせ • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023お知らせ • Jul 23Regent Pacific Group Limited Provides Consolidated Earnings Guidance for the Period Ended 30 June 2023Regent Pacific Group Limited provided consolidated earnings guidance for the period ended 30 June 2023. The group expects to record a loss attributable to the equity holders of the company for the period ended 30 June 2023 (the "Reporting Period") of between approximately USD 12 million (or approximately HKD 93.60 million) to approximately USD 15 million (or approximately HKD 117 million), which represents a substantial decrease in the loss as compared to a loss attributable to the equity holders of the Company of approximately USD 20.06 million (or approximately HKD 156.47 million) for the period ended 30 June 2022 (the "Corresponding Period").お知らせ • Feb 18Endurance RP Limited Provides Earnings Guidance for the Year Ended 31 December 2022Endurance RP Limited provided earnings guidance for the year ended 31 December 2022. For the year, the Group expects to record a loss attributable to the equity holders of the Company of between approximately USD 33 million (or approximately HKD 257.40 million) to approximately USD 36 million (or approximately HKD 280.80 million), which represents a substantial increase in the loss as compared to the loss attributable to the equity holders of the Company of approximately USD12.60 million (or approximately HKD 98.28 million) for the year ended 31 December 2021 (the Corresponding Period).収支内訳Regent Pacific Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:RPGL.F 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 250-54030 Sep 251-44030 Jun 251-44031 Mar 251-44031 Dec 241-44030 Sep 240-104030 Jun 240-154031 Mar 240-204031 Dec 230-254030 Sep 230-274030 Jun 230-294031 Mar 230-324031 Dec 220-364030 Sep 220-364-130 Jun 220-354-231 Mar 222-245-131 Dec 213-135030 Sep 214-46130 Jun 21556231 Mar 213-95131 Dec 202-245030 Sep 201-475030 Jun 200-705031 Mar 200-686031 Dec 190-666030 Sep 191-536030 Jun 191-406031 Mar 194-366031 Dec 186-316030 Sep 188-276030 Jun 1810-236031 Mar 188-256031 Dec 175-276030 Sep 173-326030 Jun 170-376031 Mar 170-207031 Dec 160-28030 Sep 16028030 Jun 16078031 Mar 160-18031 Dec 150-98030 Sep 153-158130 Jun 156-2273質の高い収益: RPGL.Fは現在利益が出ていません。利益率の向上: RPGL.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: RPGL.Fは利益を出していないが、過去 5 年間で年間12.9%の割合で損失を削減してきた。成長の加速: RPGL.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: RPGL.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。株主資本利益率高いROE: RPGL.Fの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 19:11終値2026/03/18 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Regent Pacific Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Keith RedpathCavendishSanjay JhaHybridan LLP
お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026
お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025
お知らせ • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
お知らせ • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024
お知らせ • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023
お知らせ • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kong
お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026
お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025
お知らせ • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.
お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kong
お知らせ • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
お知らせ • Dec 19Regent Pacific Group Limited Announces Submission of Senstend New Drug Application to the National Medical Products Administration in ChinaThe Board announced that commercial strategic partner Jiang Su Wan Bang Sheng Hua Yi Yao Ji Tuan You Xian Ze Ren Gong Si (Jiangsu Wanbang Biopharmaceutical Group Co. Ltd.) ("Wanbang Biopharmaceutical", a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. ("Fosun")) has submitted the New Drug Application ("NDA") registration dossier with the National Medical Products Administration ("NMPA") on 17 December 2024, with approval expected within 12 months from the submission date. Wanbang Biopharmaceutical is responsible, at its own expense, for obtaining the NDA from NMPA and maintaining any and all regulatory approvals required for the importation of Senstend in the People's Republic of China ("China" or "PRC"). In addition, and importantly, Wanbang Biopharmaceutical has signed an exclusive manufacturing and supply agreement with, inter alia, Genetic S.p. A. ("Genetic") and Jiang Su Wan Bang Yi Yao Ying Xiao You Xian Gong Si (Wanbang Pharmaceutical Marketing and Distribution Co. Ltd) ("Wanbang MKT", an affiliate of Wanbang Biopharmaceutical) on 26 August 2024, where Genetic will manufacture and supply Senstend to Wanbang Biopharmaceutical based on purchase orders received from Wanbang Biopharmaceutical. As previously mentioned, on the NDA being approved by NMPA, USD 5 million (or approximately HKD 39 million) and on first commercial launch USD 2 million (or approximately HKD 15.60 million) will be payable to the Group from Wanbang Biopharm pharmaceutical.
お知らせ • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, May 30, 2024Regent Pacific Group Limited, Annual General Meeting, May 30, 2024, at 15:00 China Standard Time. Location: 14/F, Fairmont House, 8 Cotton Tree Drive, Central Hong Kong Agenda: To receive, consider and adopt the audited financial statements of the Company and the reports of the Directors and the independent auditor of the Company for the year ended 31 December 2023; to re-appoint RSM Hong Kong as the independent auditor of the Company and to authorise the Board to fix their remuneration; to re-elect the following Directors, each as a separate ordinary resolution, and to authorise the Board to fix the remuneration of the Directors for the year ending 31 December 2024; and to consider other matters.
お知らせ • Mar 26Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million.Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million on March 24, 2024. The consideration consists of CNY 8 million in cash. As part of the consideration, CNY 8 million was paid towards common equity. . West China Coking & Gas Company Limited reported the unaudited net loss of CNY 8.9 million as at 31 December 2023. The completion of the transaction is conditional upon all necessary corporate, governmental or regulatory approvals of the Disposal (the “Conditions”) including but not limited to unanimous approval from the shareholders of the Target Company and any relevant PRC governmental or regulatory bodies.
お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024
お知らせ • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023
お知らせ • Jul 23Regent Pacific Group Limited Provides Consolidated Earnings Guidance for the Period Ended 30 June 2023Regent Pacific Group Limited provided consolidated earnings guidance for the period ended 30 June 2023. The group expects to record a loss attributable to the equity holders of the company for the period ended 30 June 2023 (the "Reporting Period") of between approximately USD 12 million (or approximately HKD 93.60 million) to approximately USD 15 million (or approximately HKD 117 million), which represents a substantial decrease in the loss as compared to a loss attributable to the equity holders of the Company of approximately USD 20.06 million (or approximately HKD 156.47 million) for the period ended 30 June 2022 (the "Corresponding Period").
お知らせ • Feb 18Endurance RP Limited Provides Earnings Guidance for the Year Ended 31 December 2022Endurance RP Limited provided earnings guidance for the year ended 31 December 2022. For the year, the Group expects to record a loss attributable to the equity holders of the Company of between approximately USD 33 million (or approximately HKD 257.40 million) to approximately USD 36 million (or approximately HKD 280.80 million), which represents a substantial increase in the loss as compared to the loss attributable to the equity holders of the Company of approximately USD12.60 million (or approximately HKD 98.28 million) for the year ended 31 December 2021 (the Corresponding Period).